Claret Targets TAVR Stroke Risk With Sentinel Embolic Filter Device
This article was originally published in The Gray Sheet
Executive Summary
The company launched the SENTINEL trial in the U.S., the first prospective, randomized, controlled, blinded trial in the U.S. of a cerebral protection device for transcatheter aortic valve replacement.